Eli Lilly's CEO sees Medicare's new policy covering obesity treatments as a pivotal moment, poised to unlock access for millions of beneficiaries to its incoming oral drug, orforglipron, and intensify the market battle with Novo Nordisk.
While Medicare provides a crucial safety net at 65, significant gaps in coverage for dental, vision, and long-term care can lead to six-figure annual expenses. Proactive planning with HSAs, specialized insurance, and strategic budgeting is essential to protect retirement savings.
Millions rely on Medicare, yet common misunderstandings about its coverage rules and costs can lead to significant financial shocks in retirement. We clarify three critical areas where assumptions often prove wrong.
UnitedHealth Group, already navigating a turbulent period, confronts a new challenge as federal regulators propose a near-flat payment increase for Medicare Advantage plans in 2027, threatening a key revenue driver for the healthcare giant.
Relocating during retirement offers new beginnings but also introduces complex financial and healthcare planning challenges. Here’s what future retirees need to know about managing Social Security and Medicare benefits ahead of a move.
Many retirees face unexpected healthcare costs, and late enrollment in Medicare can lead to lifelong surcharges. Here’s a guide to timing your sign-up and avoiding unnecessary penalties.
RBC Capital reaffirms its Outperform rating on UnitedHealth Group, citing management's commitment to long-term earnings targets, even as a lower-than-expected Medicare Advantage rate proposal triggers a sharp sell-off in the health insurer's shares.
Proposed flat payment rates for 2027 by CMS intensify margin pressures on Medicare Advantage insurers like Clover Health, raising investor concerns about cost management and growth prospects in a tightening regulatory landscape.
CNBC's Jim Cramer pointed to Humana as the S&P 500's standout loser following a pivotal Medicare Advantage rate announcement from federal regulators, triggering a sector-wide sell-off.
Skyward Specialty Insurance Group (SKWD) has launched a new Power Generation insurance solution aimed at small to mid-sized producers and brokers, offering customized coverage for a wide array of power assets and complementing its existing renewable energy program.
Major health insurers face a dual regulatory assault as a proposed freeze on Medicare Advantage payments coincides with a new Department of Labor rule targeting opaque Pharmacy Benefit Manager (PBM) practices, threatening profits on both sides of their businesses.
Despite persistent pressures in its government-backed Medicaid and Medicare businesses, Elevance Health reported Q4 performance in line with expectations, crediting strategic portfolio shifts and cost controls. CEO Gail Boudreaux outlined actions to stabilize margins, while analysts zeroed in on future risks and the growth trajectory of its commercial and Carillon health solutions segments.
Citi Research has initiated coverage on Sanofi with a Neutral rating and an €85 price target, citing pipeline setbacks and a lack of near-term catalysts. The analysis comes as the French pharma giant reports positive Phase 3 results for its eczema drug amlitelimab.
CVS Health faces a revised outlook from analysts following a key Medicare payment proposal, yet maintains its dividend payout as the healthcare giant balances regulatory challenges with its diversified business model.
Despite recent market turbulence triggered by Medicare Advantage rate announcements, Bernstein reaffirms its confidence in UnitedHealth Group with a $405 price target, even as another major firm adopts a more cautious stance.
UnitedHealth Group's fourth-quarter earnings call revealed a company in transition, as executives outlined strategic shifts to counter pressures in Medicare Advantage and Medicaid. The market's sharp sell-off reflects deep-seated concerns about medical cost trends and competitive dynamics.
Bank of America has initiated coverage on electronics manufacturing services provider Celestica with a 'Buy' rating, citing the company's strategic position to capitalize on the AI data center infrastructure boom. The firm set a price target of $400, forecasting strong growth driven by custom server and networking switch demand.
Wells Fargo lowered its price target on UnitedHealth Group (UNH) following its Q4 report and a disappointing Medicare rate proposal from regulators, highlighting pressures on the healthcare giant's key growth engine.
Erasca (ERAS) gains significant analyst momentum as Mizuho initiates coverage with an 'Outperform' rating and a $16 price target, citing confidence in its 2026 proof-of-concept milestones for RAS-targeted cancer therapies.
New CMS reimbursement rates are pressuring Medicare Advantage profits, sending shares of Humana and CVS Health lower. We analyze whether the sell-off presents a buying opportunity for dividend investors or signals deeper structural challenges.
